1. Home
  2. CTGO vs IMMP Comparison

CTGO vs IMMP Comparison

Compare CTGO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contango ORE Inc.

CTGO

Contango ORE Inc.

HOLD

Current Price

$26.00

Market Cap

439.9M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.98

Market Cap

426.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTGO
IMMP
Founded
2009
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
439.9M
426.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CTGO
IMMP
Price
$26.00
$2.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
265.5K
465.4K
Earning Date
11-13-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,306,742.00
Revenue This Year
N/A
$292.48
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.28
52 Week Low
$8.85
$1.32
52 Week High
$30.22
$3.53

Technical Indicators

Market Signals
Indicator
CTGO
IMMP
Relative Strength Index (RSI) 46.18 65.76
Support Level $26.09 $2.80
Resistance Level $28.67 $3.07
Average True Range (ATR) 1.33 0.18
MACD -0.37 -0.01
Stochastic Oscillator 2.77 60.07

Price Performance

Historical Comparison
CTGO
IMMP

About CTGO Contango ORE Inc.

Contango Ore Inc operates in the United States. The company is engaged in the exploration of gold, silver, and copper ores in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin whose governmental entity is the Tetlin Tribal Council for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: